[Chemotherapy of osteogenic sarcoma].

Area of Science:

• Pediatric Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Osteosarcoma treatment has advanced with improved surgical techniques and chemotherapy.
• The T10 chemotherapy program by Rosen demonstrates a high survival rate of 90%.

Purpose of the Study:

• To evaluate the efficacy of the T10 chemotherapy program in pediatric osteosarcoma patients.
• To assess functional outcomes and survival rates following T10 chemotherapy and surgical intervention.

Main Methods:

• Adoption of Rosen's T10 chemotherapy program in 31 pediatric osteosarcoma patients.
• Assessment of outcomes including metastasis development, survival, and surgical approach (local resection vs. amputation).

Main Results:

• Favorable results were observed in 31 treated patients with an average follow-up of 19 months.
• Only three patients developed metastases, and one patient died.
• Of the 30 surviving patients, 23 underwent local resection and 8 underwent amputation.

Conclusions:

• The T10 chemotherapy program is a reliable and effective treatment for pediatric osteosarcoma.
• Improved surgical techniques and chemotherapy contribute to better functional results and survival in osteosarcoma patients.